Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7954505 | 0.87 | — | — | |
| SCHEMBL7952186 | 0.82 | CACNA1B (0.31) | CACNA1BCACNA1CAR | |
| SCHEMBL7952826 | 0.81 | TRPA1 (0.34) | CACNA1BCACNA1CARTRPA1 | |
| SCHEMBL7952004 | 0.80 | AR (0.34) | CACNA1BAR | |
| SCHEMBL7944041 | 0.79 | MAPK1 (0.32) | — | |
| SCHEMBL7953046 | 0.79 | CA1 (0.35) | CXCR2TRPA1 | |
| SCHEMBL4259477 | 0.76 | ALDH1A1 (0.38) | CXCR2TRPA1 | |
| SCHEMBL7957201 | 0.74 | CXCR2 (0.35) | CXCR2AR | |
| SCHEMBL7957177 | 0.74 | — | — | |
| SCHEMBL7957640 | 0.74 | HDAC4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-30 | — | — | US | disclosed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | CXCR2 1357/4885EGLN1 1573/4885CACNA1B 596/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | CXCR2 1357/4885EGLN1 1573/4885CACNA1B 596/4885 |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | CXCR2 1357/4885EGLN1 1573/4885CACNA1B 596/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | CXCR2 1324/4885EGLN1 1519/4885CACNA1B 453/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | CXCR2 1357/4885EGLN1 1573/4885CACNA1B 596/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | CXCR2 1357/4885EGLN1 1573/4885CACNA1B 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.